Lyka Labs Limited Stock Price Today (NSE: LYKALABS)

Lyka Labs Limited

80.111.14 (1.40%)
Market Closed

Fundamental Score

...

Lyka Labs Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Lyka Labs Limited share price today is 80.11, down 1.40% on NSE/BSE as of 16 September 2026. Lyka Labs Limited (LYKALABS) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of 289.62 (Cr). The 52-week high for LYKALABS share price is 101.90 and the 52-week low is 44.10. The company has a Return on Equity (ROE) of -10.24% and a debt-to-equity ratio of 0.52.

Lyka Labs Limited Share Price Chart — NSE/BSE Historical Performance

No data
High
81.51
Low
66.64
Volume
14.7K
Change
+19.74%

Lyka Labs Limited share price chart: 19.74% return over the past month. 52-week high ₹101.90, 52-week low ₹44.10.

Lyka Labs Limited — Last 10 Trading Days

DateOpenHighLowCloseVolume
80.0080.1179.9080.1110.55K (Cr)
82.5082.5081.2581.253.89K (Cr)
84.0084.0082.8082.908.27K (Cr)
83.2184.8083.2184.2048.87K (Cr)
83.1483.1483.1483.1426.23K (Cr)
81.5181.5181.5081.5145.25K (Cr)
79.9279.9279.9179.9211.49K (Cr)
78.3678.3678.3678.3631.84K (Cr)
75.0076.8373.9076.8323.07K (Cr)
73.0075.3373.0075.3315.30K (Cr)

Lyka Labs Limited — Last 12 Months Price History

MonthOpenHighLowCloseChange
75.3684.8073.0080.11+6.30%
60.8076.5860.3075.36+23.95%
74.8177.0058.0060.80-18.73%
60.4877.0554.6573.95+22.27%
59.7567.9957.0058.30-2.43%
45.8061.9945.8059.70+30.35%
62.0862.3844.1044.95-27.59%
72.3073.8560.2062.35-13.76%
75.1084.7070.2171.74-4.47%
79.9986.9072.2075.89-5.13%
94.0496.0079.0680.42-14.48%
96.67100.9491.5894.04-2.72%

Returns & Performance

Poor

Return on Equity (ROE)

-10.24%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

-6.75%

Returns generated on total capital deployed

Excellent

Oper. Profit Margin (5Y Avg)

18.61%

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Lyka Labs Limited Valuation Check

Price to Earnings (P/E)

N/A

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

34.89x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

58.16%

% shares held by company founders/management

Poor

FII Holding

0.29%

% shares held by foreign institutional investors

Poor

DII Holding

0.66%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Excellent

Profit Growth (Quarterly YoY)

107.31%

Net profit growth vs same quarter last year

Excellent

Revenue Growth (Quarterly YoY)

28.11%

Revenue growth vs same quarter last year

Poor

Revenue Growth (5-Year CAGR)

8.29%

Compounded annual revenue growth over 5 years

Poor

EPS Growth (5-Year CAGR)

4.19%

Earnings per share growth over 5 years

Poor

Net Profit Growth (5-Year CAGR)

0.77%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Poor

Debt to Equity Ratio

0.52x

Total debt ÷ equity. Below 0.5 = financially healthy

Poor

Interest Coverage Ratio

-2.54x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

45.40 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Lyka Labs Limited Fundamental Analysis & Valuation Benchmarking

Educational evaluation of LYKALABS across key market metrics for learning purposes.

Positive Indicators

6 factors identified

Strong Operating Margins (18.61%)

Observation: Healthy 5-year operating margins indicate pricing power and cost control.

Analysis: OPM >15% suggests operational efficiency and competitive advantages.

Robust Profit Growth (107.31%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture.

Strong Revenue Growth (28.11%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential.

Strong Cash Generation (₹45.40 Cr over 5Y)

Observation: Healthy free cash flow generation supports growth and returns.

Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.

Balanced Promoter Holding (58.16%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

7 factors identified

Below-Average Return on Equity (-10.24%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Suboptimal ROCE (-6.75%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.

Weak Earnings Growth (4.19% CAGR)

Observation: Below-average 5-year EPS growth performance.

Analysis: Low EPS growth may not keep pace with inflation.

Stagnant Profit Growth (0.77% CAGR)

Observation: Limited 5-year profit growth trajectory.

Analysis: Low profit growth may indicate scalability challenges or market maturity.

Weak Interest Coverage (-2.54x)

Observation: Limited ability to service debt obligations from earnings.

Analysis: Low interest coverage raises concerns about financial stability.

Limited Institutional Interest (FII+DII: 0.95%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Lyka Labs Limited vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Lyka Labs Limited with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
18.9/100
80
₹289.62
-10.24%
Poor
-6.75%
Poor
0.5
Good
0.77%
Average
8.29%
Good
0.00%
66.4/100
1877
₹450228.65
37.2
Average
14.74%
Average
19.31%
Good
0.0
Excellent
31.64%
Excellent
11.78%
Good
0.82%
56.3/100
9426
₹249775.75
85.5
Average
16.19%
Good
20.38%
Excellent
0.0
Excellent
5.29%
Good
8.67%
Good
0.41%
51.4/100
4927
₹166759.24
78.7
Average
27.07%
Excellent
14.09%
Average
1.8
Average
11.56%
Good
11.80%
Good
0.76%
74.1/100
1139
₹113642.26
25.4
Average
19.74%
Good
21.77%
Excellent
0.4
Excellent
18.76%
Excellent
12.45%
Good
0.09%
40.2/100
1370
₹110675.45
32.8
Average
11.82%
Average
15.67%
Good
0.0
Excellent
10.03%
Good
8.01%
Good
0.90%
34.1/100
1926
₹104025.14
95.0
Average
18.19%
Good
21.35%
Excellent
0.5
Excellent
-1.89%
Poor
7.19%
Good
0.13%
24.6/100
1675
₹96391.01
26.2
Average
9.94%
Poor
14.54%
Average
0.2
Excellent
-8.07%
Poor
6.32%
Good
0.26%
83.4/100
2100
₹96017.92
17.4
Average
26.90%
Excellent
31.80%
Excellent
0.3
Excellent
34.39%
Excellent
13.02%
Good
0.72%
41/100
1141
₹95306.90
29.5
Average
11.75%
Average
14.80%
Average
0.2
Excellent
16.54%
Excellent
12.09%
Good
0.65%
61.5/100
2289
₹94539.83
46.3
Average
12.49%
Average
13.56%
Average
0.4
Excellent
10.52%
Good
18.10%
Excellent
0.04%

Lyka Labs Limited PE Ratio History

Historical price-to-earnings ratio for LYKALABS — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 20252.25₹75.8933.7x
FY 202213.57₹129.709.6x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Lyka Labs Limited Quarterly Performance

Latest quarterly metrics for LYKALABS — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

28.11%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

107.31%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

8.29%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

0.77%

Compounded annual net profit growth over 5 years

Lyka Labs Limited Technical Indicators

SMA 50, SMA 200, RSI and volume signals for LYKALABS — calculated from daily price history

78RSI 14
Overbought — RSI 78

Momentum is strong — price may be stretched. Watch for pullbacks.

SMA 50
70
▲ Price above SMA 50 — Short-term bullish
SMA 200
68
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
18K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Lyka Labs Limited Financial Statements

Annual income statement, balance sheet and cash flow for Lyka Labs Limited (LYKALABS) — sourced from NSE/BSE filings.

Financial Results & Statements

Latest quarterly, annual and period-wise financial data for Lyka Labs Limited

Loading latest quarterly results...

About LYKALABS (Lyka Labs Limited)

Lyka Labs Ltd is a dynamic pharmaceutical entity deeply rooted in the Indian landscape, operating at the intersection of innovative drug development and robust manufacturing practi...ces. With a firm commitment to healthcare advancements, the company meticulously crafts a diverse portfolio of pharmaceutical formulations and active pharmaceutical ingredients (APIs), addressing a spectrum of therapeutic needs. Lyka Labs dedicates significant resources to research and development, constantly seeking to refine existing products and pioneer novel solutions that contribute to improved patient outcomes. The company's operational strategy focuses on maintaining rigorous quality control measures throughout the entire production process, from raw material sourcing to final product distribution, ensuring safety and efficacy. By fostering a culture of scientific excellence and ethical business practices, Lyka Labs is poised to continue its growth trajectory within the ever-evolving pharmaceutical sector. The company’s diverse product line demonstrates its commitment to catering to varied health and wellness requirements. Their formulations encompass a range of therapeutic areas, featuring specialized skincare solutions designed to soothe, protect, and rejuvenate. From gentle emollients and targeted topical steroids to potent antifungal and antibacterial treatments, Lyka Labs addresses common dermatological concerns with precision. Beyond skincare, the company also offers effective acne management therapies, pain relief medications, and scientifically formulated anti-aging products. Additionally, their range extends to essential personal care items such as cleansing lotions, hair care products designed to combat dandruff, and sunscreens for sun protection, reflecting a dedication to overall well-being and preventative healthcare. Lyka Labs' product development philosophy emphasizes both efficacy and safety, utilizing advanced formulations and rigorous testing protocols. Lyka Labs' strategic vision involves expanding its reach and impact within the pharmaceutical market. This expansion encompasses strengthening existing product lines through continuous innovation and strategic partnerships to introduce new and effective therapies to the market. The company places a strong emphasis on building lasting relationships with healthcare professionals and stakeholders, ensuring that their products are readily accessible to patients who need them. With a robust infrastructure, a skilled workforce, and a dedication to ethical business practices, Lyka Labs is well-positioned to navigate the complexities of the pharmaceutical industry and achieve sustainable growth. Through its commitment to quality, innovation, and patient-centric care, Lyka Labs remains a key player in shaping the future of healthcare in India and beyond.

Company Details

Symbol:LYKALABS
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Kunal Narendra Gandhi
MD, CEO, Promoter & Director
Mr. Yogesh Babulal Shah
CFO & Executive Director
Mr. Shailendra Kumar Agrawal CS
Company Secretary & Compliance Officer

LYKALABS Share Price: Frequently Asked Questions

What is the current share price of Lyka Labs Limited?

Lyka Labs Limited (LYKALABS) trades at ₹80.11 on NSE and BSE. Market cap ₹289.62 (Cr). Educational data only.

What is the P/E ratio of Lyka Labs Limited?

Lyka Labs Limited has a P/E of N/Ax vs industry average 34.89x.

What is the Bull Run score for Lyka Labs Limited?

Lyka Labs Limited has a Bull Run score of 18.9/100 based on 25+ financial parameters.

Does Lyka Labs Limited pay dividends?

Lyka Labs Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Lyka Labs Limited?

Lyka Labs Limited has ROE of -10.24%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Lyka Labs Limited?

Lyka Labs Limited has debt-to-equity of 0.52.

Is Lyka Labs Limited a good investment?

Bull Run gives Lyka Labs Limited a score of 18.9/100. This is not investment advice — consult a SEBI-registered advisor.